{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-017082","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2026-05-14T20:36:14+00:00","discovered_at":"2026-05-14T20:37:00.275323+00:00","generated_at":"2026-05-14T20:38:21.267027+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Valion Bio posts Q1 net loss of $6.2M; cash falls to $7.2M; advances Entolimod","bullets":["Net loss $6.2M ($2.23/share) vs $1.5M ($2.52/share) a year ago; operating expenses $5.6M (was $1.4M).","Cash and equivalents $7.2M at March 31, 2026, down from $12.6M at Dec 31, 2025.","Government engagement broadened with BARDA, NIAID, and Dept of War for Entolimod as ARS countermeasure.","Velocity Bioworks CDMO integration advancing; facility supports internal and third-party biologics manufacturing.","Pipeline includes Entolimod (Animal Rule pathway) and Entolasta (TLR5 agonist for oncology supportive care)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-017082","json":"https://secwatch.observer/filing/0001437749-26-017082.json","markdown":"https://secwatch.observer/filing/0001437749-26-017082.md","text":"https://secwatch.observer/filing/0001437749-26-017082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000143774926017082/0001437749-26-017082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000143774926017082/tivc20260405_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:38:21.267027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21d3c677e732dd00378d1c807062ac4175b638fa","claim":"Valion Bio, Inc. reported financial results for the three months ended March 31, 2026.","evidence_excerpt":"Valion Bio Reports First Quarter 2026 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000143774926017082/0001437749-26-017082-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}